

Florent Mouliere

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/977712/publications.pdf>

Version: 2024-02-01

48
papers

6,238
citations

304602

22
h-index

360920

35
g-index

58
all docs

58
docs citations

58
times ranked

8869
citing authors

#	ARTICLE	IF	CITATIONS
1	Liquid biopsies come of age: towards implementation of circulating tumour DNA. <i>Nature Reviews Cancer</i> , 2017, 17, 223-238.	12.8	1,786
2	Enhanced detection of circulating tumor DNA by fragment size analysis. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	670
3	Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. <i>Nature Medicine</i> , 2014, 20, 430-435.	15.2	582
4	Circulating cell free DNA: Preanalytical considerations. <i>Clinica Chimica Acta</i> , 2013, 424, 222-230.	0.5	461
5	High Fragmentation Characterizes Tumour-Derived Circulating DNA. <i>PLoS ONE</i> , 2011, 6, e23418.	1.1	440
6	Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats. <i>Neurobiology of Disease</i> , 2008, 31, 316-326.	2.1	285
7	Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. <i>Nucleic Acids Research</i> , 2010, 38, 6159-6175.	6.5	267
8	Toward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNA. <i>Cancer Cell</i> , 2019, 36, 350-368.	7.7	204
9	Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. <i>Molecular Oncology</i> , 2014, 8, 927-941.	2.1	192
10	Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care. <i>Clinical Cancer Research</i> , 2016, 22, 3067-3077.	3.2	144
11	Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load. <i>Translational Oncology</i> , 2013, 6, 319-328.	1.7	143
12	Circulating tumor-derived DNA is shorter than somatic DNA in plasma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 3178-3179.	3.3	128
13	Detection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	123
14	ctDNA monitoring using patient-specific sequencing and integration of variant reads. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	116
15	The value of cell-free DNA for molecular pathology. <i>Journal of Pathology</i> , 2018, 244, 616-627.	2.1	91
16	The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, S209-S215.	1.4	78
17	Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer. <i>Scientific Reports</i> , 2017, 7, 5554.	1.6	73
18	Measurement of Plasma Cell-Free Mitochondrial Tumor DNA Improves Detection of Glioblastoma in Patient-Derived Orthotopic Xenograft Models. <i>Cancer Research</i> , 2019, 79, 220-230.	0.4	67

#	ARTICLE	IF	CITATIONS
19	Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors. <i>Genome Medicine</i> , 2020, 12, 23.	3.6	66
20	Fragmentation patterns and personalized sequencing of cell-free DNA in urine and plasma of glioma patients. <i>EMBO Molecular Medicine</i> , 2021, 13, e12881.	3.3	61
21	A phylogenetic latent feature model for clonal deconvolution. <i>Annals of Applied Statistics</i> , 2016, 10, .	0.5	42
22	Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA. <i>Genome Research</i> , 2022, 32, 215-227.	2.4	41
23	Cell-free DNA technologies for the analysis of brain cancer. <i>British Journal of Cancer</i> , 2022, 126, 371-378.	2.9	24
24	Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	19
25	Cell-Free DNA Fragmentomics: The New "Omics" on the Block. <i>Clinical Chemistry</i> , 2020, 66, 1480-1484.	1.5	18
26	Refined characterization of circulating tumor DNA through biological feature integration. <i>Scientific Reports</i> , 2022, 12, 1928.	1.6	18
27	The Effect of Preanalytical and Physiological Variables on Cell-Free DNA Fragmentation. <i>Clinical Chemistry</i> , 2022, 68, 803-813.	1.5	16
28	Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors. <i>Oncotarget</i> , 2018, 9, 32570-32579.	0.8	15
29	Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients " initial observations. <i>PLoS ONE</i> , 2020, 15, e0231884.	1.1	11
30	PCR-Free Shallow Whole Genome Sequencing for Chromosomal Copy Number Detection from Plasma of Cancer Patients Is an Efficient Alternative to the Conventional PCR-Based Approach. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1553-1563.	1.2	7
31	Circulating DNA analysis and concordance with tumor section analysis in the detection of KRAS and BRAF point mutations from metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10505-10505.	0.8	5
32	Personalized Medicine by Analyzing Circulating DNA: Application to the Management Care of Colorectal Cancer Patients. <i>Annals of Oncology</i> , 2013, 24, i7.	0.6	2
33	P3.12 Circulating Dna Analysis in The Era of Personalized Cancer Medicine: Application to Kras/Braf Point Mutations Detection in Colorectal Cancer. <i>Annals of Oncology</i> , 2012, 23, v36-v37.	0.6	1
34	Individualised monitoring of patients with metastatic melanoma using plasma DNA. <i>Lancet</i> , The, 2017, 389, S99.	6.3	1
35	PD56-03 DETECTION OF PRIVATE CLONAL MUTATIONS IN LOCALISED PROSTATE CANCER FROM RARE MOLECULES OF CIRCULATING TUMOUR DNA. <i>Journal of Urology</i> , 2018, 199, .	0.2	0
36	EP-1368 Circulating cell free DNA during chemoradiotherapy in non-small cell lung cancer patients. <i>Radiotherapy and Oncology</i> , 2019, 133, S747-S748.	0.3	0

#	ARTICLE	IF	CITATIONS
37	Circulating tumor DNA (ctDNA) analysis by low-coverage whole genome sequencing (lcWGS) of resectable esophageal adenocarcinoma (rEAC) patients.. Journal of Clinical Oncology, 2021, 39, 4033-4033.	0.8	0
38	Abstract LB-78: Detection of circulating cell-free DNA is enhanced by targeting short fragments: high concordance of theKRASandBRAFmutation status from plasma analysis, with tumor-tissue analysis in colorectal cancer... , 2013, , .		0
39	Circulating DNA as a strong multimarker prognostic tool in metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2014, 32, 3604-3604.	0.8	0
40	CALIBRATE: Intensive profiling of circulating tumour DNA (ctDNA) from patients participating in experimental therapeutics trials including mutational profiles and copy number changes.. Journal of Clinical Oncology, 2016, 34, 11530-11530.	0.8	0
41	A pilot study of individualised monitoring of patients with metastatic melanoma using plasma and urine DNA.. Journal of Clinical Oncology, 2017, 35, e21032-e21032.	0.8	0
42	LBA-14â€¦COMPREHENSIVE CHARACTERISATION OF CIRCULATING TUMOUR DNA IN PLASMA AND URINE OF PATIENTS WITH RENAL TUMOURS: RESULTS OF THE DIAMOND AND MONREC STUDIES. Journal of Urology, 2019, 201, .	0.2	0
43	Abstract 1367: Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors. , 2019, , .		0
44	Abstract 736: ctDNA detection in early stage non-small cell lung cancer. , 2020, , .		0
45	Title is missing!. , 2020, 15, e0231884.		0
46	Title is missing!. , 2020, 15, e0231884.		0
47	Title is missing!. , 2020, 15, e0231884.		0
48	Title is missing!. , 2020, 15, e0231884.		0